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Background and Introduction
Parasitic diseases, which can be transmitted by insect or animal vectors, blood or tissue donation, 
congenitally, or through contaminated food or water, cause a devastating burden for hundreds of 
millions of people around the world and in the United States. The parasitic diseases of primary 
public health importance include malaria, the neglected tropical diseases, and some neglected 
parasitic infections in the United States.
Malaria
Between 2001 and 2013, an estimated 4.2 
million lives were saved as a result of a scale-
up of science-based malaria interventions, 
through collaborative efforts of the Global 
Fund, the President’s Malaria Initiative, and 
Roll Back Malaria partners including endemic 
countries. Still, malaria continues to pose 
an enormous health burden worldwide. The 
World Health Organization estimates that 
in 2013 malaria caused 584,000 deaths and 
approximately 198 million illnesses (clinical 
episodes). Approximately 3.2 billion people 
(half the world’s population) in 97 countries/
territories live in areas at risk of malaria. 
Malaria was eliminated in the United States 
in the late 1940’s. However, the United States 
continues to be vulnerable to importations 
of disease as long as they exist elsewhere; 





Neglected tropical diseases affect more than 
1 billion people—one-sixth of the world’s 
population—largely in rural areas of low-
income countries. These diseases cause a 
large toll on endemic populations, including 
lost ability to attend school or work, growth 
retardation in children, impairment of 
cognitive skills and development in young 
children, and place a serious economic burden 
on entire countries. Seven parasitic neglected 
tropical diseases—lymphatic filariasis, 
onchocerciasis, schistosomiasis, infections 
from soil-transmitted helminths (hookworm, 
Ascaris, whipworm), and trachoma can be 
controlled or even eliminated by providing 
safe and effective medicines to individuals 
in affected communities through mass drug 
administration. Several of the drugs used for 
mass drug administration have activity against 
more than one neglected tropical disease. 
Along with mass drug administration, efforts 
to control the mosquitoes, blackflies, and other 
vectors that transmit these diseases, and to 
improve basic water, sanitation, and hygiene 
are highly effective against these neglected 
tropical diseases. Mass drug administration-
based programs are considered one of the best 
buys in public health—with a cost of about 
$0.10 to $0.50 per person/year, resulting 
in the benefit of helping prevent or treat 
several different diseases. CDC also focuses 
on Guinea worm disease; while not treated 
with mass drug administration there has been 
a large collaborative effort to provide health 
education, good medical management, and 
increase the use of low-tech filters for drinking 
water. As a result this devastating disease is 
now on the verge of being eradicated.
Neglected Parasitic Infections
Parasitic infections still occur in the United 
States and cause serious illnesses, including 
seizures, blindness, infertility, heart failure, 
and even death. CDC has targeted five parasitic 
infections as priorities for public health action, 
based on the numbers of people infected, 
the severity of the illnesses or their resulting 
conditions, and our ability to prevent and 
treat them. These include Chagas disease, 
neurocysticercosis, toxocariasis, toxoplasmosis, 
and trichomoniasis. Most infections can be 
prevented, and many are treatable, but more 
awareness and action are needed.
➤➤ 300,000 people living in the United States 
are infected with the parasite that causes 
Chagas disease, and it is estimated that 
more than 300 babies are congenitally 
infected every year.
➤➤ Every year an estimated 70 people, most of 
them children, are blinded by toxocariasis.
➤➤ 2,000 people are diagnosed with 
neurocysticercosis every year, a leading 
cause of adult onset seizures.
➤➤ Toxoplasmosis, a leading cause of 
foodborne illness and death, chronically 
affects more than 6 million people.
➤➤ Every year 8 million people are newly 
infected with trichomoniasis, which 
has been associated with infertility and 
preterm labor in women, resulting in low 
birthweight babies.
Significant progress has been made to reduce the burden of these parasitic diseases; however, key 
challenges remain. The purpose of this strategic framework is to articulate CDC’s goals, objectives, 
and strategies to effectively address parasitic disease health threats during the next five years. 
Vision, Mission, and Values
➤➤Vision
Fewer Parasitic Diseases—Healthier People
➤➤Mission
To protect and improve the health of Americans and the global community from 
parasitic disease threats through evidence based public health action
➤➤Core Values 
Our work is guided by a commitment to science, service, partnership, and stronger 
public health capacity. We continually strive to: 
➤➤ Apply science to improve public health:  
We rigorously conduct research and apply the principles of laboratory, clinical, 
epidemiologic science, and related disciplines to address critical public health 
needs, translate research findings into policy guidance and program interventions, 
and evaluate the impact of public health programs.
➤➤ Provide service:  
We share our technical expertise and public health experience with health partners 
and the public, and strive to identify and address health needs and reduce the 
impact of parasitic diseases domestically and around the world.
➤➤ Engage in partnership to achieve common goals:  
We coordinate our activities in collaboration with a wide array of partners to more 
effectively and efficiently reduce the impact of parasitic diseases.
➤➤ Build public health capacity:  
We work with domestic and global health partners to design, implement, and 
evaluate programs that monitor, prevent, and control parasitic diseases in order to 
strengthen overall health system performance, capacity, and sustainability.
Strategic Goals
CDC is committed to working with domestic and global partners towards achieving 
progress in three primary areas during the next five years:
1. Protect the United States 
Reduce death, illness, and disability from parasitic diseases in the United States 
2. Eliminate the Global Burden 
Eliminate the global burden of malaria and targeted neglected tropical diseases
3. Advance Research 
Advance research to detect, prevent, and eliminate parasitic diseases
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Goal 1:  Reduce death, illness, and disability from parasitic 
diseases in the United States
1.1 Improve monitoring of parasitic diseases in the  
United States 
1.2 Improve diagnosis and detection of parasitic 
diseases in the United States
1.3 Increase capacity of clinical providers to 
diagnose and manage patients with parasitic 
diseases
1.4 Increase awareness of parasitic diseases through 
effective health communication and education 
1.5 Reduce the risk of transmission of targeted 
parasitic infections in the United States
As the nation’s public health 
agency, CDC has a mandate to 
protect people from health threats 
including parasitic diseases. 
Six parasitic diseases, including 
malaria, are nationally notifiable 
in the U.S., meaning CDC works 
with states to monitor rates 
of disease to detect potential 
increases.
Fast and accurate diagnosis is 
vital to effective treatment and 
improved health. CDC provides 
timely and accurate information 
and consultation to the public, 
physicians, laboratories, and other 
partners to ensure appropriate 
diagnosis and treatment of 
parasitic diseases. Real-time 
diagnosis saves an average of 
$75 per specimen and reduces 
the wait time for results from 48 
hours to 30 minutes. Through 
the CDC Drug Service, otherwise 
unavailable life-saving drugs 
can be provided to health care 
providers for treatment of patients 
with parasitic diseases.
Dozens of parasites have serious 
health impacts on Americans, 
including seizures, blindness, 
infertility, and heart failure. 
CDC has targeted five neglected 
parasitic infections (Chagas 
disease, neurocysticercosis, 
toxocariasis, toxoplasmosis, and 
trichomoniasis) as priorities for 
public health action, based on the 
numbers of people infected, the 
severity of the illnesses, or our 
ability to prevent and treat them.
Goal 2:  Eliminate the global burden of malaria and targeted 
neglected tropical diseases
2.1 Increase scientific leadership and global capacity to 
support elimination of parasitic diseases 
2.2 Accelerate elimination of malaria
2.2.1 Accelerate elimination of malaria transmission from 
the Island of Hispaniola
2.2.2 Accelerate elimination of malaria in southeast 
Asia to help curb the global spread of malaria drug 
resistance 
2.2.3 Advance diagnostic tool development for use in low 
transmission settings to achieve malaria elimination 
2.2.4 Maintain assistance for certification of malaria 
elimination in eligible countries
2.3 Improve and accelerate malaria control programs, 
including co-implementing the President’s Malaria 
Initiative and the Amazon Malaria Initiative
2.4 Expand scientific leadership and technical support 
to accelerate eradication and elimination of targeted 
neglected tropical diseases
2.4.1 Accelerate global eradication of Guinea worm 
disease
2.4.2 Accelerate elimination of lymphatic filariasis in 
Haiti 
2.4.3 Strengthen global capacity to eliminate lymphatic 
filariasis globally, onchoceriasis in the Americas 
and Africa, and blinding trachoma as a public 
health problem 
2.5 Strengthen global capacity to control soil-transmitted 
helminths and schistosomiasis 
2.6 Advance the next group of neglected tropical diseases 
prioritized for control or elimination, to become “tool 
ready” for public health scale up
2.7 Strengthen surveillance systems to provide quality 
data for decision making 
2.7.1 Establish routine surveillance systems to detect and 
monitor parasitic diseases
2.7.2 Improve the quality of existing surveillance systems 
to ensure collection of timely, complete, and useful 
data 
2.7.3 Assist countries to integrate program-specific 
surveillance needs into routine systems
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Much of the global burden 
from parasitic disease is due to 
malaria and a group of neglected 
tropical diseases. 
Due to the high burden of 
malaria and neglected tropical 
diseases, unprecedented 
investments have been made 
to control or eliminate many of 
them. Elimination targets have 
been set for malaria, lymphatic 
filariasis, onchocerciasis, and 
blinding trachoma.
The most sustainable approach 
to address a health threat is to 
eliminate it. Disease elimination 
requires robust surveillance 
and response to inform data-
driven approaches, both to use 
resources wisely and to measure 
impact.   
Evidence-based guidance 
is needed to inform and 
assist countries and partners 
with decisions around the 
effectiveness and optimal mix 
of interventions, the scale 
down of interventions, and post 
treatment surveillance. 
Malaria and neglected tropical 
diseases are still threats to 
U.S. travelers, the military, and 
to U.S. citizens living abroad.  
Prevention messages need to 
be reinforced, but global efforts 
toward elimination/eradication 
will help to reduce the global 
risk for everyone.
Goal 3:  Advance research to detect, prevent, and eliminate 
parasitic diseases
3.1 Strengthen the evidence base to support 
elimination of parasitic diseases 
3.2 Develop and evaluate tools and interventions 
targeting the mosquito vectors that transmit 
malaria
3.3 Develop and evaluate tools and interventions 
targeting the malaria parasite
3.4 Develop and evaluate interventions to improve 
case management of malaria 
3.5 Optimize the effectiveness and mix of 
interventions
3.6 Develop and validate epidemiological and 
analytical tools for detection and surveillance of 
targeted neglected tropical diseases
3.7 Evaluate the impact of parasitic disease control 
programs on other endemic diseases 
3.8 Improve global research capacity for parasitic 
disease prevention and control through technical 
assistance and training 
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Tremendous success has been 
achieved towards reducing burden 
of malaria and neglected tropical 
diseases, but progress is fragile. 
Program successes achieving 
lowered transmission and drug or 
insecticide resistance are creating 
shifting burden and technical 
challenges that require new tools 
and approaches, as well as better 
information and ability to adapt to 
new epidemiological landscapes.
There is evidence of growing 
insecticide and drug resistance 
for malaria. Insecticide resistance 
in malaria vectors has been 
reported in 53 of 65 countries 
around the world since 2010.  
Neglected tropical disease 
elimination programs need data 
to inform decisions about when 
to stop mass drug administration 
and effective approaches to 
detect disease reoccurrence.
Research on new tools and 
approaches—to reduce 
transmission completely 
and to overcome technical 
challenges—will be needed to 
support elimination, including 
diagnostics, strategic use of 
treatment drugs, surveillance 
methods, vector control 
strategies, and vaccines. 
The United States and Global Health Context
The Division of Parasitic Diseases and Malaria’s work is aligned with multiple higher level USG 
and global strategies, including those highlighted below. 
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The Global Fund to Fight AIDS, Tuberculosis and Malaria
www.theglobalfund.org/en/
The Global Fund is designed to accelerate the end of AIDS, tuberculosis, and 
malaria as epidemics. Founded in 2002, the Global Fund is a partnership between 
governments, civil society, the private sector, and people affected by the diseases. The 
Global Fund raises and invests nearly US$4 billion a year to support programs run by 
local experts in more than 140 countries. 
Global Health Security Agenda 
www.cdc.gov/globalhealth/security/index.htm
The Global Health Security Agenda is an effort in partnership with U.S. government 
sister agencies, other nations, international organizations, and public and private 
stakeholders, to accelerate progress toward a world safe and secure from infectious 
disease threats and to promote global health security as an international security 
priority, to:
➤➤ Prevent and reduce the likelihood of outbreaks—natural, accidental, or 
intentional;
➤➤ Detect threats early to save lives;
➤➤ Respond rapidly and effectively using multi-sectoral, international coordination 
and communication.
The U.S. will work with partner countries on eleven action packages to prevent, 
detect, and effectively respond to infectious disease threats. 
Global Program to Eliminate Lymphatic Filariasis
www.who.int/lymphatic_filariasis/disease/en/
In 1997, the World Health Organization (WHO) classified lymphatic filariasis as 
eradicable or potentially eradicable. In that same year, the World Health Assembly 
(WHA) adopted Resolution WHA 50.29, which called on member states to initiate 
steps to eliminate lymphatic filariasis as a public health problem. In response to this 
call, WHO launched the Global Programme to Eliminate Lymphatic Filariasis in 2000. 
The elimination strategy has two components: (1) to stop the spread of infection 
(interrupting transmission); and (2) to alleviate the suffering of affected populations 
(controlling morbidity). 
Guinea Worm Disease Eradication Program 
www.who.int/dracunculiasis/eradication/en/
In 1981, the WHO’s decision-making body, the WHA, adopted resolution WHA 
34.25, which recognized that the International Drinking Water Supply and Sanitation 
Decade presented an opportunity to eliminate dracunculiasis (Guinea worm disease). 
This led to WHO and the CDC formulating the strategy and technical guidelines for an 
eradication campaign of dracunculiasis. 
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Onchocerciasis Elimination Program for the Americas (OEPA)
www.who.int/blindness/partnerships/onchocerciasis_oepa/en/
OEPA is a regional initiative with the goal of eliminating morbidity and interrupting 
transmission of river blindness in six endemic countries in the Americas: Brazil, 
Colombia, Ecuador, Guatemala, Mexico, and Venezuela distributed in 13 foci. The 
OEPA strategy is to encourage the endemic countries to provide sustained ivermectin 
mass drug administration treatment every six months.
President’s Malaria Initiative (PMI)
www.pmi.gov/
The goal of the PMI, launched in 2005, was to reduce malaria-related mortality by 
50 percent across 15 high-burden countries in sub-Saharan Africa through a rapid 
scale-up of four proven and highly effective malaria prevention and treatment 
measures. Under the PMI Strategy for 2015-2020, PMI will take a strategic approach 
which emphasizes the following five areas: (1) achieving and sustaining scale of 
proven interventions, (2) adapting to changing epidemiology and incorporating new 
tools, (3) improving countries’ capacity to collect and use information, (4) mitigating 




The Rollback Malaria Partnership is the global framework to implement coordinated 
action against malaria. It mobilizes for action and resources and forges consensus 
among partners. The Partnership is comprised of more than 500 partners, including 
malaria endemic countries, their bilateral and multilateral development partners, the 
private sector, nongovernmental and community-based organizations, foundations, 
and research and academic institutions.
USAID’s Neglected Tropical Diseases (NTD) Program 
www.neglecteddiseases.gov/
In February 2008, the Neglected Tropical Diseases Initiative was launched with a 
pledge to make available $350 million over 5 years to deliver integrated neglected 
tropical disease treatment to 300 million people in Africa, Asia, and Latin America. 
This program is making large-scale, cost-effective contributions to the global effort to 
reduce the economic and epidemiologic burden of neglected tropical diseases.
WHO Global Malaria Technical Strategy 
www.who.int/malaria/areas/global_technical_strategy/en/ 
The World Health Organization’s global technical strategy for malaria articulates the 
vision and goals for malaria over the next decade and brings together current policy 
recommendations in a comprehensive, evidence-based strategy for WHO member 
states to use in developing their own strategies, on their pathway to elimination.
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